India Pharma Outlook Team | Friday, 24 July 2026
The pharmaceutical and healthcare industry continues to evolve rapidly, driven by policy changes, strategic investments, scientific breakthroughs, and regulatory developments.
This news highlights developments influencing the global and Indian pharmaceutical landscape.
From concerns over potential US tariffs on generic medicines and India's resilient healthcare deal activity. It also covers advances in AI-powered drug discovery and breakthrough obesity therapies.
Below are today's key stories industry stakeholders should not miss.
Potential US tariffs on pharmaceutical imports may lead to higher prices for generic medicines, according to an Indian pharmaceutical executive. Industry leaders caution that additional duties could increase healthcare costs for American patients while placing pressure on India's export-driven pharmaceutical sector and global medicine supply chains.
“Right now, we are operating on a very thin margin,” Namit Joshi, chair of the Pharmaceuticals Export Promotion Council of India, said in an interview.
India's pharmaceutical and healthcare sector recorded a deal value of USD 13.9 billion during the second quarter, demonstrating continued investor confidence. While the number of transactions declined compared to previous quarters, higher-value strategic investments helped maintain strong overall deal activity.
Sanofi India has received relief after tax authorities withdrew a tax demand amounting to INR 72.71 lakh. The decision removes a regulatory overhang for the company and strengthens its compliance position while eliminating a pending financial liability.
Boston Consulting Group believes India is well-positioned to become a global pharmaceutical innovation hub over the next decade. Expanding research capabilities, a skilled talent pool, digital transformation, and strong manufacturing infrastructure are expected to drive the country's next phase of pharmaceutical growth.
Priyanka Aggarwal, India and South East Asia Leader, Healthcare Practice at Boston Consulting Group (BCG) said, “Over the last few years, we feel that there is an inflection point now where Indian companies are also investing significantly in innovation, and we can see the results of that as well. We now have at least 10 plus original assets, molecules which have been discovered… and therefore we now feel that these are the green shoots of innovation, and this is not just coincidental it's built on a full stack approach.”
NASA scientists are investigating the possibility of producing medicines in space by leveraging tobacco plants and engineered viruses. The research aims to support long-duration space missions while also unlocking new approaches to pharmaceutical manufacturing on Earth.
Tatva Chintan Pharma Chem has announced plans to set up its Dahej III greenfield manufacturing facility in Gujarat as part of its long-term expansion strategy. The new plant is expected to strengthen production capabilities, support demand across specialty chemicals and pharmaceutical intermediates, and reinforce the company's manufacturing footprint.
Indian equity markets witnessed another subdued trading session, with pharmaceutical stocks extending their losses alongside the broader market. Persistent investor caution and sector-specific selling weighed on leading pharma companies, contributing to the second consecutive day of declines.
Also Read: AI in Drug Discovery and Development: From Lab to Commercial Market
Novartis India reported strong financial performance for theQ1, registering a 16 percent increase in net profit and an 18 percent rise in revenue compared to the previous year. Despite the positive earnings, the company's shares declined during trading as investors assessed the quarterly results.
Eli Lilly announced encouraging clinical trial results for Retatrutide, with participants living with Type 2 diabetes achieving nearly 20 percent average weight loss. The company plans to submit the therapy for regulatory approval in the first quarter, strengthening its position in the rapidly growing obesity treatment landscape.
"With the positive results across five Phase 3 studies, we now have the clinical data package to support global submissions for retatrutide and look forward to working with regulators as they evaluate this first-of-its- kind medicine," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health.
Artificial intelligence is poised to dramatically transform pharmaceutical research by reducing drug discovery timelines to approximately one year. AI-driven platforms are enabling researchers to identify drug candidates faster, lower development costs, and improve efficiency across early-stage drug discovery.
"It usually takes about 4.5 years to get to a drug developmental candidate using the traditional approach. But if a pharma company has a research lab in China ... they cut two years of time," said, Alex Zhavoronkov , CEO, Insilico.
The latest developments across the pharmaceutical and healthcare sector underscore the industry's continued transformation through policy shifts, investment activity, manufacturing expansion, scientific research, and digital innovation.
From evolving global trade dynamics and robust healthcare investments to advances in AI-driven drug discovery and next-generation therapies, these developments highlight the opportunities and challenges shaping the future of the pharmaceutical ecosystem.
As the industry continues to innovate and adapt, these trends will remain critical for businesses, investors, researchers, and healthcare stakeholders alike.
